TCO GROUP HOLDINGS, L.P. sold $92.5M of INNV

TCO GROUP HOLDINGS, L.P. sold 10,000,000 shares of InnovAge Holding Corp. (INNV) at $9.25 ($92.50M total) on 2026-09-24.

Original reporting
SEC EDGAR · TCO GROUP HOLDINGS, L.P.
Published Sep 28, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 29, 2026, 2:46 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$INNV
Bearish
high confidence
Mentioned
$INNV
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INNVBearishMed
01

Why it matters

The disclosed sale reduces insider ownership and may signal reduced confidence, prompting short interest.

02

Market read

First‑report insider sale of significant size; traders may adjust positions on INNV.

03

What to watch

Potential upcoming clinical data or partnership announcements not disclosed.

Relevance 8/10Novelty 8/10Timing: post-market today

Background

SEC Form 4 filing by TCO GROUP HOLDINGS, L.P., a 10% owner of InnovAge Holding Corp.

Company-level read

Ticker impact

$INNVBearishHigh confidence
Context

Form 4 shows a 10% owner sold 10,000,000 shares for $92.5M, reducing ownership to 102,576,555 shares.

Expected impact

likely pressure as the market prices in the insider sell.

Evidence & confidence

The sale represents a $92.5M cash outflow by a major shareholder, which traders often interpret as a bearish signal.

Market effects

Minimal impact on the broader biotech sector; the move is company‑specific.

U.S. market only; no regional spillover.

Low global relevance.

Counterpoint

The insider may be diversifying without negative outlook; price could hold.

Key entities

  • InnovAge Holding Corp.

    Biotech firm listed on NASDAQ under INNV.

  • TCO GROUP HOLDINGS, L.P.

    Investment vehicle holding a 10% stake in INNV.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$INNVMed

InnovAge settles DOJ civil claims for $37 million

InnovAge Holding Corp. (INNV) settled civil claims with the DOJ for $37 million, covering alleged conduct from 2016 to 2022. The company did not admit wrongdoing. InnovAge provides senior healthcare programs and has invested in compliance and operations. As of September 2026, it served 8,420 participants across 20 centers in six states.

$INNVMed

InnovAge (INNV) Q1 2027 Earnings Call Transcript

InnovAge (INNV) reported Q1 2027 revenue of $264.8M, up 12.1% YoY, and adjusted EBITDA of $31.3M, up 75%. The company cited growth in census and profitability, investments in clinical and operational capabilities, and plans for expansion. Management discussed the impact of the V28 Medicare risk adjustment model, noting differences between PACE and Medicare Advantage.

$INNVMed

What InnovAge (INNV) Said on Its Q1 Earnings Call

InnovAge (INNV) reported Q1 cost of care rose 12.7% to $85.5M, citing growth and higher expenses. The company is investing in care teams and technology to reduce costs. InnovAge reaffirmed its fiscal 2027 guidance, expecting revenue of $1.05B-$1.085B and adjusted EBITDA of $105M-$115M. Medicare rates are expected to increase 1.5%-2% from Jan 1, 2024.

$INNVHigh

INNOVAGE ANNOUNCES FINANCIAL RESULTS FOR THE FISCAL FIRST QUARTER ENDED SEPTEMBER 30, 2026

InnovAge Holding Corp. (INNV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 INNOVAGE ANNOUNCES FINANCIAL RESULTS FOR THE FISCAL FIRST QUARTER ENDED SEPTEMBER 30, 2026 DENVER, CO., November 3, 2026 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare